Ensemble Therapeutics Corporation Receives Two Notices of Allowance for Fundamental Patents to DNA-Programmed Chemistry Process for Novel Macrocycle Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing Ensemblins™, a novel class of small molecule therapeutics with the power of biologics, today announced that the US Patent and Trademark Office (USPTO) has issued two Notices of Allowance relating to patents licensed exclusively by Harvard University to Ensemble. These newly allowed claims encompass broad and fundamental aspects of DNA-Programmed Chemistry (DPC) molecular library construction, affirming Ensemble’s novel and proprietary approach to building diverse libraries of molecules for drug discovery.